Omigapil clinical trials
Also written TCH346.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2002
How each study uses omigapil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Novartis Pharmaceuticals (2) · Novartis (2) · Santhera Pharmaceuticals (1)
Studies
Open first, then newest update. How each study uses omigapil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)CompletedPhase 1Santhera PharmaceuticalsNCT01805024Written as Omigapil
- A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral SclerosisCompletedPhase 2Novartis PharmaceuticalsNCT00036413Written as TCH346
- Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2Novartis PharmaceuticalsNCT00072709Written as TCH346
- A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)CompletedPhase 2NovartisNCT00230074Written as TCH346
- A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and EfficacyCompletedPhase 1/2NovartisNCT00407212Written as TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
Codes
What other systems call omigapil · ClinicalTrials.gg INT004054
- UNII (FDA) 5V14HD0N4QOMIGAPILConfirmed FDA, Wikidata
- Wikidata Q7090184omigapilConfirmed FDA, Wikidata
- NCI Thesaurus C97362OmigapilOne source FDA
- DrugBank DB12879One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5V14HD0N4Q | OMIGAPIL | Confirmed FDA, Wikidata |
| Wikidata | Q7090184 | omigapil | Confirmed FDA, Wikidata |
| NCI Thesaurus | C97362 | Omigapil | One source FDA |
| DrugBank | DB12879 | — | One source Wikidata |
Also registered as omigapil maleate (UNII 3Q69BFZ4OP).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.